• Clinical Trials - Pancreatic cancer

    Study Objective Contact
    A Phase 2, Randomized, Multicenter Study of PEGPH20 (PEGylated Recombinant Human Hyaluronidase) Combined with nab-Paclitaxel Plus Gemcitabine Compared with nab-Paclitaxel Plus Gemcitabine in Subjects with Stage IV Previously Untreated Pancreatic Cancer [LCID Study Number: 2013-035] This protocol compares the effects of standard of care treatment (nab-paclitaxel and gemcitabine) to the standard of care plus PEGPH20 in patients with stage IV pancreatic cancer. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.
    Biomarkers for Early Detection of Pancreatic Cancer in Patients with New-Onset Diabetes Mellitus [LCID Study Number: 2015-062] To develop a screening blood test that can help identify people with diabetes who are at risk of having pancreatic cancer. Enrollment by invitation only. Principal Investigator(s):
    Thomas Schnelldorfer, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Katherine A. Wasilewsky.
    Compassionate Use of HyperAcute-Pancreas (algenpantucel-L) Immunotherapy in Subject with Surgically Resected Pancreatic Cancer [LCID Study Number: 2013-018] The purpose of this study is to give patients diagnosed with pancreatic cancer the opportunity to receive standard of care therapy (gemcitabine) with the addition of HyperAcute®-Pancreas immunotherapy. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Francis W. Nugent, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Deborah J. Gannon.
    E2211: A Randomized Phase II Study of Temozolomide or Temozolomide and Capecitabine in Patients with Advanced Pancreatic Neuroendocrine Tumors [LCID Study Number: 2013-040] This protocol addresses whether the combination of temozolomide and capecitabine works better than temozolamide alone on advanced pancreatic neuroendocrine tumor cancer. This study is no longer accepting new patients. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Charles A. Stagno-Scotto,
    Erin H. Hartnett.
    Molecular Analysis of Cancer [LCID Study Number: 2011-048] The purpose of this research is to discover molecular changes involved in cancer. We hope that a better understanding of these changes can improve cancer management. This research may include genetic and/or genomic analysis (tests to determine and compare your genetic sequence, or DNA). Some of the tissue we collect for our research may be submitted to the National Cancer Institute Cancer Genome Atlas Project. The goal of this project is to determine the genomic changes involved in more than 20 types of human cancer. Principal Investigator(s):
    Kimberly R. Christ, PhD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Doreen L. Browne, ,CCRP,
    Jane S. Nalwalk,
    Linda M. Topjian.
    Phase I/II Study Of RAD001 In Combination With Temozolomide In Patients With Advanced Pancreatic Neuroendocrine Tumors [LCID Study Number: 2008-036] The purpose of this research is to test the safety and efficacy of an investigational drug, RAD001, in combination with temozolomide in patients with pancreatic neuroendocrine tumors. THIS STUDY IS NO LONGER ACCEPTING NEW PATIENTS. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Sherry G. Heldt, RN.
    RTOG 0848: A Phase II-R and A Phase III Trial Evaluating Both *Erlotinib (PH II-R)and Chemoradiation (PH III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma [LCID Study Number: 2014-018] To determine whether the use of 5-FU with radiation following post-surgery chemotherapy further enhances survival for such patients who do not show disease progression after 5 cycles of chemotherapy. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Amanda M. Pietras,
    Charles A. Stagno-Scotto.
    S1505, A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine /NAB-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma [LCID Study Number: 2015-073CIRB] To assess 2-year overall survival in each treatment arm (mFOLFIRINOX and gemcitabine/nab-paclitaxel) in patients with resectable pancreatic cancer. b. If the stated threshold is met in one or both arms: to choose the better regimen with respect to 2-year overall survival. Principal Investigator(s):
    Keith E. Stuart, MD

    For more information about this Research Study call 781-744-8027.

    Study Coordinator(s):
    Erin H. Hartnett.